Barrett’s Esophagus Test Identifies High-Risk Patients Missed by Standard Pathology
A study of 85 patients shows the TissueCypher test detected 15% with elevated cancer progression risk despite a non-dysplastic diagnosis.
A study of 85 patients shows the TissueCypher test detected 15% with elevated cancer progression risk despite a non-dysplastic diagnosis.
Color Health is providing free COVID testing through the CDC's Increasing Community Access to Testing program.
Ortho Clinical Diagnostics has a distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's Vitros QC Solutions to Vitros System customers worldwide.
The all-in-one diagnostic platform combines hematology, biochemistry, and immunoassay testing in a single run.
The test offers sensitivity comparable to next-generation sequencing methods while using noninvasive blood specimens instead of bone marrow aspirates.
Labcorp will deploy Roche’s cobas Mass Spec platform in its US labs, marking the first commercial rollout of this fully automated mass spectrometry system to streamline complex diagnostic testing workflows.
The qPCR-based test detects variants that increase risk of severe fluoropyrimidine chemotherapy toxicity.
The technology is designed to deliver high-purity long RNA to support CRISPR and functional genomics workflows.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.